DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Arimoclomol
Arimoclomol
Optumrx Brand Pipeline Forecast
Safety and Tolerability of Arimoclomol in Patients with Sporadic Inclusion Body Myositis: a Randomised, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial
Pioneering New Markets Changing the Standard of Care
Horizon Scanning Status Report June 2019
Molecules
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
The Clinical Trial Landscape in Amyotrophic Lateral Sclerosis—Past, Present, and Future
Pharmaceutical Appendix to the Harmonized Tariff Schedule
Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
(12) Patent Application Publication (10) Pub. No.: US 2013/0224110 A1 Bynoe (43) Pub
Pharmacological Induction of Molecular Chaperones Restores Mitochondrial Function in Hyperglycemically Stressed Sensory Neurons by Liang Zhang
Horizon Scanning Status Report June 2020 Prepared For: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036
Randomized, Double-Blind, Placebo-Controlled Trial of Arimoclomol in Rapidly Progressive SOD1 ALS
High Potential Disruption Report May 2020
Orphan Drug Designation List
Product List
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Optumrx Brand Pipeline Forecast
Top View
ALS Treatment and Trials Björn Oskarsson, MD, FAAN Mayo Clinic Florida 2019 Financial Disclosure
Bedfordshire, Luton and Milton Keynes CCG High Cost Drugs
ICH Protocol Template
Customs Tariff - Schedule Xxi - 1
Quest Issue 2, Summer 2019
Customs Tariff - Schedule Xxi - 1
Neurological Disease
Heat Shock Protein–Based Therapy As a Potential Candidate for Treating the Sphingolipidoses
Orphan Drug Designations and Approvals List As of 12‐01‐2014
Company Update – April 2020 Important Notice
2018 Medicines in Development for Neurological Disorders a Report on Disorders of the Brain, Spinal Cord and Nerves
WO 2012/170676 Al 13 December 2012 (13.12.2012) P O P C T
Pbr Excluded Drugs List
INVESTIGATING NOVEL THERAPEUTIC APPROACHES for SPORADIC INCLUSION BODY MYOSITIS (Sibm)
Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016